换一批A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
第一作者：
Meina,Liang
第一单位：
Clinical and Quantitative Pharmacology, BioPharmaceuticals Research and Development, AstraZeneca, 121 Oyster Point Blvd., South San Francisco, California, 94080, USA. meina.liang@astrazeneca.com.
作者：
医学主题词
动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗体, 中和(Antibodies, Neutralizing);生物学标记, 药理学(Biomarkers, Pharmacological);细胞系, 肿瘤(Cell Line, Tumor);药物评价, 临床前(Drug Evaluation, Preclinical);半衰期(Half-Life);人类(Humans);成束猴(Macaca fascicularis);小鼠(Mice);模型, 生物学(Models, Biological);肿瘤(Neoplasms);血小板源性生长因子(Platelet-Derived Growth Factor);受体, 血小板源生长因子α(Receptor, Platelet-Derived Growth Factor alpha)
DOI
10.1208/s12248-020-00523-3
PMID
33210183
发布时间
2021-09-27
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
